News | January 14, 2009

Stereotactic Biopsy Reveals Undetected Prostate Cancer

January 14, 2009 – After performing stereotactic transperineal prostate biopsy on 747 patients, researchers concluded that forty percent of men with prostate cancer may not even know they have it, according to research study published in a recent issue of Urology.

The study by the Prostate Cancer Foundation of Chicago revealed the standard office biopsy procedure often isn’t enough to properly detect prostate cancer. This new research will be published in an upcoming issue of Urology.

Researchers used an advanced biopsy technique called stereotactic transperineal prostate biopsy (STPB) on patients with persistent elevated prostate specific antigen (PSA) levels who previously had at least one negative office biopsies. All patients had received transrectal prostate biopsies (TRPB), administered by a urologist.

“Men who have negative transrectal biopsies and continue to have elevated PSA levels should consider STPB because 40 percent will harbor malignancy,” said Michelle Braccioforte, director of research and education for the Prostate Cancer Foundation of Chicago. “Our level of confidence is greatly enhanced with regards to the presence or absence of cancer, and more specifically, the exact location of the cancer within the prostate.”

STPB is performed by taking a median of 40 samples of the prostate through the perineum while the patient is under general anesthesia. Performed as an outpatient procedure, it allows more comprehensive sampling, compared to the transrectal method, which takes fewer samples through the rectum. In addition, by taking more samples during STPB, the exact location of the cancer can be pinpointed.

Between April 2004 and January 2008, 747 patients with high PSA levels were studied. All patients had been tested using TRPB at least once and all results had been negative. All patients received the STPB. Biopsy results identified the presence of cancer in 291 (39 percent) of the patients.

“The information obtained from this kind of comprehensive biopsy allows us to design and perform more sophisticated treatment plans”, says Brian Moran, M.D., medical director of the Prostate Cancer Foundation of Chicago and the Chicago Prostate Cancer Center (www.prostateimplant.com). This procedure is also a stepping stone towards focal therapy, where more limited treatment can result in less side effects, yet achieve cure rates equal to more radical forms of treatment.”

For more information: www.chicagoprostatefoundation.org

Related Content

SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Overall survival of metastatic patients with SABR presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
News | Radiation Oncology | October 30, 2018
October 30, 2018 — In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggre
Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018

Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018.

Feature | Stereotactic Body Radiation Therapy (SBRT) | October 23, 2018 | By Greg Freiherr
With its shorter course of treatment,...
CyberKnife System Provides Excellent Prostate Cancer Survival Rates in Five or Fewer Sessions
News | Stereotactic Body Radiation Therapy (SBRT) | September 27, 2018
Accuray Inc. announced that published data from two prospective, multi-center studies using differing protocols provide...
First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System
News | Stereotactic Body Radiation Therapy (SBRT) | April 06, 2018
Accuray Inc. and Erasmus MC announced the first patient has been successfully treated using an online-adaptive (OA)...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Age Impacts Post-treatment Mortality for Early-stage Lung Cancer Patients

Image courtesy of Henri Becquerel Cancer Center

News | Stereotactic Body Radiation Therapy (SBRT) | January 24, 2018
A University of Colorado Cancer Center study published in the Journal of Clinical Oncology explores mortality in the...
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...